Your session is about to expire
← Back to Search
Treatment (revumenib, daunorubicin, cytarabine) for Acute Myeloid Leukemia
Study Summary
"This trial is testing the safety and effectiveness of a new drug called SNDX-5613 in combination with standard chemotherapy for treating patients with a specific type of leukemia. SNDX-5613 works by
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are individuals above the age of 18 eligible for participation in this trial?
"To be eligible for this research study, participants must be between 18 and 75 years old."
Are participants currently being recruited for enrollment in this clinical trial?
"Information available on clinicaltrials.gov shows that this investigation is presently seeking suitable participants. The trial's initial posting was on November 10, 2024, and its latest revision took place on March 8, 2024."
What is the upper limit of participants involved in this clinical study?
"Yes, as per the details on clinicaltrials.gov, this research is presently enrolling participants. It was initially posted on November 10th, 2024 and last modified on March 8th, 2024. The study aims to enlist 28 individuals at a single site."
Is it possible for me to participate in this medical study?
"This clinical trial aims to recruit 28 individuals aged between 18 and 75 who are currently diagnosed with acute myeloid leukemia. Eligible participants should meet the subsequent criteria: Suitable for intensive induction chemotherapy, have specific genetic mutations related to AML, possess a performance status within defined limits, exhibit normal liver and kidney function as well as viral infection control, including HIV treatment adherence and undetectable HBV or HCV viral loads if applicable; also allowed are patients with non-interfering prior malignancies."
What are the potential risks associated with administration of revumenib, daunorubicin, and cytarabine as a treatment option for individuals?
"Given that this is a Phase 1 trial with sparse safety and efficacy data, the Power team ranks the safety of Treatment (revumenib, daunorubicin, cytarabine) at level 1."
Share this study with friends
Copy Link
Messenger